ライフサイエンスコーパス: medical device

1 such as surgery or presence of an indwelling medical device.

2 formation of a biofilm on the surface of the medical device.

3 the shaved scalp and connected to a portable medical device.

4 ly interface with an off-the-shelf, approved medical device.

5 particularly when associated with indwelling medical devices.

6 t tissue-lubricating dysfunction and to coat medical devices.

7 event thrombotic occlusion and biofouling of medical devices.

8 e storage material to power certain types of medical devices.

9 sent regulatory hurdles for use in temporary medical devices.

10 s on a variety of host tissues and implanted medical devices.

11 biofilm-associated infections on indwelling medical devices.

12 a role in early stage infection of implanted medical devices.

13 key challenges to the optimal performance of medical devices.

14 le maintaining high shear adhesion to secure medical devices.

15 the development of novel bio-optoelectronic medical devices.

16 ing the analysis of potentially contaminated medical devices.

17 tly recovered from soft tissue and retrieved medical devices.

18 nts related to security and privacy risks of medical devices.

19 may be relevant to the development of other medical devices.

20 n central venous catheters and perhaps other medical devices.

21 consumer electronics but not in implantable medical devices.

22 rug-delivery systems, bone-graft fillers and medical devices.

23 ange membranes, protein crystallization, and medical devices.

24 ffectiveness of prescription medications and medical devices.

25 d infection of surgical sites and indwelling medical devices.

26 of novel biosensor platforms and a range of medical devices.

27 ociated with biofilms attached to indwelling medical devices.

28 regenerating organs and engineering new-age medical devices.

29 nged length of stay, and the use of invasive medical devices.

30 can cause life-threatening interference with medical devices.

31 c surfaces in vitro as well as on indwelling medical devices.

32 s, are a cause of infections associated with medical devices.

33 ysaccharide capsule and can form biofilms on medical devices.

34 others, civic activities, and inventions of medical devices.

35 f infections often associated with implanted medical devices.

36 capsule and can form biofilms in prosthetic medical devices.

37 long as they are kept > or =3 feet from all medical devices.

38 s, from robotics to perhaps even implantable medical devices.

39 nfections by biofilm formation on indwelling medical devices.

40 terized by biofilm development on indwelling medical devices.

41 practicing physician increasingly relies on medical devices.

42 . epidermidis during infection of indwelling medical devices.

43 central venous catheter insertion sites, and medical devices.

44 tion related to biofilm formed on indwelling medical devices.

45 odes, supercapacitors, water/air filters and medical devices.

46 and better recall procedures are needed for medical devices.

47 ofilms on the surfaces of various indwelling medical devices.

48 ions such as those associated with implanted medical devices.

49 licone-containing or non-silicone-containing medical devices.

50 nsulators, solid supports for catalysis, and medical devices.

51 is often precluded by the poor visibility of medical devices.

52 uld power sometimes in the future integrated medical devices.

53 that limit sustainable operation of wearable medical devices.

54 ibility and reduce infection associated with medical devices.

55 hich uses nanostructured mineral coatings on medical devices.

56 of online communication, cars and implanted medical devices.

57 can compromise the performance of implanted medical devices.

58 eter blockage, or biofilm formation on other medical devices.

59 effectiveness as a power source for wearable medical devices.

60 mplication resulting from biofilm fouling of medical devices.

61 ome this key challenge in the development of medical devices.

62 n the U.S. have access to safe and effective medical devices.

63 assessment of safety risks of newly approved medical devices.

64 electronics, micro-devices, and implantable medical devices.

65 tolerant infections in humans and fouling of medical devices.

66 tions associated with the use of implantable medical devices.

67 ell-designed, valid postmarketing studies of medical devices.

68 fied from Class 2 medical devices to Class 3 medical devices, a policy change that will prompt additi

69 These bacteria can also attach to implanted medical devices and develop surface-associated biofilm c

70 on that can lead to the failure of implanted medical devices and discomfort for the recipient.

71 ve played an enormous role in the success of medical devices and drug delivery systems.

72 nd their use in consumer products, including medical devices and food storage, and therefore requires

73 dida albicans and Candida glabrata adhere to medical devices and form drug-resistant biofilms.

74 ne using two nested categories that included medical devices and glossary terms attributable to the U

75 lms, which are a major concern for implanted medical devices and in many diseases.

76 ns also readily forms biofilms on indwelling medical devices and mucosal tissues, which serve as an i

77 The growing demand for compact point-of-care medical devices and portable instruments for on-site env

78 elaborate a biofilm involved in adherence to medical devices and resistance to host defenses.

79 The miniaturization of medical devices and the progress in image processing hav

80 ding generation of biocompatible implantable medical devices and tissue scaffolds.

81 ce the development of self-powered implanted medical devices and wearable/portable electronics.

82 tic biofuel cells (BFCs) may power implanted medical devices and will rely on the use of glucose and

83 ons such as wireless powering of implantable medical devices and wireless charging of stationary elec

84 ships between physicians and pharmaceutical, medical device, and other medically related industries h

85 rgical intervention, consider treatment with medical devices, and actively seek nonpharmacologic alte

86 ts, preventing inappropriate colonization in medical devices, and combatting bacterial infections.

87 vention of wound infections, colonization of medical devices, and nosocomial transmission of microorg

88 s in the control group received all standard medical, device, and disease management strategies avail

89 findings may be particularly translatable to medical device applications.

90 ich may offer a new strategy for a number of medical device applications.

91 ean Union (EU) are weighing reforms to their medical device approval and post-market surveillance sys

92 e and German Federal Institute for Drugs and Medical Devices approval.

93 Medical devices are common in clinical practice and have

94 Candida biofilms formed on indwelling medical devices are increasingly associated with severe

95 frequent inflammatory responses to implanted medical devices are puzzling in view of the inert and no

96 Emerging micro-scale medical devices are showing promise, whether in deliveri

97 thority guiding the FDA in the regulation of medical devices are summarized and discussed, including

98 blem because they commonly form on implanted medical devices, are drug resistant and are difficult to

99 at govern the approved and unapproved use of medical devices as well as device premarket evaluation a

100 l designated investigational drugs, and some medical devices, as well as documented patient harm and

101 y has broad applications in blood-contacting medical devices, as well as various other applications r

102 Medical device-associated infections involve the attachm

103 oist surfaces on Earth and cause chronic and medical device-associated infections.

104 bicans, whose biofilms are a major source of medical device-associated infections.

105 Candida species are a major cause of medical device-associated infections.

106 olonizer of human skin and a common cause of medical device-associated infections.

107 of a quorum-sensing inhibitor can eliminate medical device-associated staphylococcal infections.

108 d health are driving innovations in wearable medical devices at a tremendous pace.

109 Traditional antibiotic therapy to control medical device-based infections typically fails to clear

110 ustry reduced early-stage research, favoring medical devices, bioengineered drugs, and late-stage cli

111 ategies to fabricate ECM-like interfaces for medical devices, but also offers the capability of spati

112 Bacterial colonisation of indwelling medical devices by coagulase-negative staphylococci is a

113 Biofilm infections of certain indwelling medical devices by common pathogens such as staphylococc

114 sents an attractive and emerging paradigm in medical devices by harnessing simultaneous advantages af

115 mising platform for generating a large-scale medical device capable of augmenting liver function in a

116 n and can be prospectively translated into a medical device capable of molecular imaging.

117 nement of ventricular assist devices (VADs), medical devices capable of maintaining circulatory outpu

118 sity, German Federal Institute for Drugs and Medical Devices, Carlos III Spanish Health Institute, Eu

119 ng of extracorporeal circuits and indwelling medical devices cause significant morbidity and mortalit

120 Ensuring the safety of medical devices challenges current surveillance approach

121 tober 2004 brought together leaders from the medical device community, including clinical investigato

122 We suggest that medical devices could be coated with RIP to prevent infe

123 Flexible medical devices designed for monitoring human vital sign

124 NISs are emerging medical devices designed to allow persons with paralysis

125 Although AEDs are complex medical devices designed to function during life-threate

126 This has significant health implications for medical device development in the future that can be use

127 damentally important to the integrity of the medical device development process.

128 policies aimed at encouraging transformative medical device development would have their greatest eff

129 en evaluated in clinical trials for drug and medical device development.

130 ing many of the stakeholders associated with medical device development.

131 ts sponsored or supported by pharmaceutical, medical device, diagnostics, and biotechnology companies

132 utility of the recently In Vitro Diagnostic Medical Devices Directive-approved Roche COBAS AmpliPrep

133 and clinical exposures from DEHP-plasticized medical devices, e.g., blood bags, hemodialysis tubing,

134 Many devices, including implantable medical devices, enter the market through a regulatory p

135 Medical device epidemiology is a relatively new field co

136 siderations in pharmacoepidemiology apply to medical device epidemiology.

137 ly evaluated by computer-based surveillance, medical device errors have no comparable surveillance te

138 Medical device events as detected by computer-based flag

139 Despite advances in medical device fabrication and antimicrobial treatment t

140 Medical devices face nonspecific biofouling from protein

141 l industry and the largest biotechnology and medical device firms accounted for 58% of total funding.

142 dustry, large biotechnology firms, and large medical device firms.

143 ins with adhesion to host cells or implanted medical devices followed by biofilm formation.

144 t may eventually lead to a low-cost personal medical device for chronic disease early detection, diag

145 nd Drug Administration approval in 1988 as a medical device for the treatment of CTCL patients, one o

146 y Congress to facilitate the availability of medical devices for "orphan" indications, ie, those affe

147 put are vital to screening food products and medical devices for chemical or biochemical contaminants

148 e development of injectable hydrogels as new medical devices for controlled delivery and filling purp

149 the guise of tissue engineering scaffolds or medical devices for drug delivery.

150 ery vehicles in addition to tablets, such as medical devices for example.

151 ion approvals for new molecular entities and medical devices for indications within the neurosciences

152 greatly facilitate applications in portable medical devices for on-the-spot diagnosis and even the p

153 re sufficient to wirelessly power a range of medical devices from outside of the body.

154 nal luminal imaging probe (EndoFLIP; Crospon Medical Devices, Galway, Ireland).

155 The development of new implantable medical devices has been limited in the past by slow adv

156 Biofilm formation on implanted medical devices has severe consequences for human health

157 surgical procedures, imaging modalities, and medical devices have improved therapy for many patients

158 Modern pharmaceuticals and medical devices have provided substantial benefits to pa

159 , traditionally defined as materials used in medical devices, have been used since antiquity, but rec

160 It could play an important role in wearable medical devices if they can be fabricated on flexible su

161 tes in human blood and urine for implantable medical devices (IMDs) was investigated.

162 f Gordonia araii infection associated with a medical device in an immunocompetent patient.

163 can form biofilms on polystyrene plates and medical devices in a process that requires capsular poly

164 ng biofilms frequently develop on indwelling medical devices in hospitalized patients, and Staphyloco

165 te of research with regard to both drugs and medical devices in order to highlight their limits and t

166 dation facilitated surface re-engineering of medical devices in situ after in vivo implantation throu

167 and Drug Administration also approved 1,679 medical devices in the neurosciences for use.

168 ponsible for the safety and effectiveness of medical devices in the United States.

169 ccess to early-stage, potentially beneficial medical devices in the United States.

170 stimations of risk associated with implanted medical devices in UCTD cases were explored in a compari

171 crucial step in the development of implanted medical devices, in vivo diagnostics, and microarrays is

172 films are notorious for forming on implanted medical devices, including catheters, pacemakers, dentur

173 Medical devices increasingly depend on computing functio

174 ents and faculty with the pharmaceutical and medical device industries.

175 nvolving professional medical societies, the medical device industry, and the FDA.

176 nsight into the observed correlation between medical device infection and thromboembolism; the increa

177 Although most experimental models of medical device infection draw upon isolated bacterial bi

178 we study, to our knowledge, a new model for medical device infection-that of an infected fibrin clot

179 r case to the 16 Gordonia species-associated medical device infections reported to date.

180 athogen that is one of the leading causes of medical device infections.

181 is is a major cause of healthcare-associated medical device infections.

182 The effects of electrostimulation, medical devices, injectable bulking agents, and local es

183 ed Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Need for Life

184 Introducing new medical devices into routine practice raises concerns be

185 Microbial colonization of medical devices is a widespread problem that tests the l

186 The ability to form biofilms on medical devices is an important aspect of pathogenesis i

187 The funding landscape for medical devices is becoming increasingly difficult and c

188 The process of assuring the safety of medical devices is constrained by reliance on voluntary

189 e engaged in research to develop implantable medical devices is to develop mechatronic implantable ar

190 need for new therapeutic advances and novel medical devices is urgent.

191 alf of which can be attributed to indwelling medical devices, is a strong risk factor for thromboembo

192 used anticoagulant in drug formulations and medical devices, is critical to ensuring public health.

193 o its ability to form biofilms on indwelling medical devices, it has emerged as a leading cause of no

194 ical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research; and

195 rm communities (called biofilms) on inserted medical devices, leading to infections that affect many

196 A paradigm shift for implantable medical devices lies at the confluence between regenerat

197 Innovative medical devices make major contributions to patient welf

198 the general public, clinical community, and medical device manufacturers with a more accurate unders

199 ase professionals to understand that fomites/medical devices may be a source of HAIs.

200 n reinforcing polymers, adhesives, textiles, medical devices, metallic alloys, and even concrete.

201 es used to support FDA approval of high-risk medical device modifications, fewer than half were rando

202 Endoscopes, including bronchoscopes, are the medical devices most frequently associated with outbreak

203 vestigated in recent reports, which involved medical devices, nanoparticles, quantum dots and nanofib

204 Surface biofouling of medical devices occurs as a result of nonspecific adhesi

205 an that comparative effectiveness studies of medical devices often necessitate additional and differe

206 High-risk medical devices often undergo modifications, which are a

207 ckings are the most widely used non-invasive medical device on the market and are believed to reduce

208 Bacteria that adhere to implanted medical devices or damaged tissue can encase themselves

209 e of 20 to 70 times that exposure from other medical devices or procedures, such as transfusions, dia

210 on of contaminated products, use of invasive medical devices, or variances in practices and procedure

211 sumer products (including soaps, toothpaste, medical devices, plastics, and fabrics) that are regulat

212 Medical devices play a vital role in diagnosing, treatin

213 surveillance methods yielded higher rates of medical device problems than found with traditional volu

214 include the inadequacy of trial research on medical devices, problems with industry-sponsored trials

215 rdioverter-defibrillators (ICDs) are complex medical devices proven to reduce mortality in specific h

216 Medical devices provide an ecological niche for microbes

217 ion of functional coatings on titanium-based medical devices provides osseoinductive bioactive molecu

218 Few studies have quantitatively assessed medical device regulation in either the US or EU.

219 review to find empirical studies evaluating medical device regulation in the US or EU.

220 strengths and weakness of the approaches to medical device regulation in these settings.

221 Medical device regulation recently has undergone major c

222 ly cephalosporins, and strategies to prevent medical device-related infection and cross-infection in

223 ic Staphylococcus aureus biofilm-associated, medical device-related infections.

224 n a number of activities aimed at mitigating medical device-related TASS outbreaks.

225 que has the potential to assess biosensor or medical device responses in complex biological matrices.

226 Current approaches for postmarket medical device safety surveillance are limited in their

227 rly warnings in the postmarket evaluation of medical device safety.

228 to form Candida biofilms on three different medical device substrates (denture strips, catheter disk

229 rug Administration (FDA) evaluates high-risk medical devices such as cardiac implantable electronic d

230 roperties could be used to coat a variety of medical devices such as catheters as well as industrial

231 al of entry included surgery and presence of medical devices such as catheters or adhesive tape.

232 tility of l-DOPA in the field of implantable medical devices, such as biosensors, as well as tissue e

233 Candida spp. adhere to medical devices, such as catheters, forming drug-toleran

234 Candida spp. infect medical devices, such as venous and urinary catheters, b

235 Postmarket medical device surveillance in the United States depends

236 The incorporation of complex medical device technologies into clinical practice is go

237 nical clutch system was developed for use in medical devices that access tissue and tissue compartmen

238 ions are associated with the implantation of medical devices that act as points of entry for the path

239 an adverse event associated with implantable medical devices that contain allergenic materials like n

240 ss Pathway was designed as a new program for medical devices that demonstrated the potential to addre

241 the development of revolutionary implantable medical devices that extract the power they require from

242 defibrillators (ICDs) are generally reliable medical devices that have the potential to add quality y

243 ation is a major complication of implantable medical devices that results in therapeutically challeng

244 of small silicon chips (used to mimic small medical devices) that were coated with the composite for

245 actice of medicine and in the development of medical devices, the study of the heart in three dimensi

246 Drug Administration (FDA) approves high-risk medical devices, those that support or sustain human lif

247 pair were recently reclassified from Class 2 medical devices to Class 3 medical devices, a policy cha

248 combination of MDD technologies with classic medical devices to create multifunctional MDD devices th

249 to their use in many products, ranging from medical devices to industrial cutting tools.

250 s regulatory landscape to successfully bring medical devices to patients.

251 his is utilized in antibacterial coatings on medical devices to reduce nosocomial infection rates.

252 y on cutting-edge diagnostic and therapeutic medical devices to serve patients.

253 on in technologies ranging from experimental medical devices to telecommunications and airport securi

254 s at multiple scales, ranging from miniature medical devices to wearable robotic exoskeletons to larg

255 (CE Mark Study for the Harpoon Medical Device [TRACER]; NCT02768870).

256 omedical critical care systems, the types of medical devices used, and their applicability to disaste

257 lococcus aureus forms biofilms on indwelling medical devices using a variety of cell-surface proteins

258 s inhibited bacterial spread from indwelling medical devices, we have provided proof of principle tha

259 Different injectable bulking agents and medical devices were associated with similar continence

260 ction is a major complication of implantable medical devices, which provide a scaffold for biofilm fo

261 The introduction of new and more complex medical devices will likely increase the risk that such

262 fouling, but also promote the integration of medical devices with the biological environment.

263 med within a host, for example on indwelling medical devices, would also differ depending on the natu